COVID-19-related myocarditis and cholinergic anti-inflammatory pathways

dc.creatorLiu, Weike
dc.creatorLiu, Zhendong
dc.creatorLi, Yue-Chun
dc.date.accessioned2020-12-09T20:58:05Z
dc.date.accessioned2022-09-23T18:08:11Z
dc.date.available2020-12-09T20:58:05Z
dc.date.available2022-09-23T18:08:11Z
dc.date.created2020-12-09T20:58:05Z
dc.identifier1109-9666
dc.identifierhttps://doi.org/10.1016/j.hjc.2020.12.004
dc.identifierhttp://hdl.handle.net/20.500.12010/16432
dc.identifierhttps://doi.org/10.1016/j.hjc.2020.12.004
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3496004
dc.description.abstractCoronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently in a pandemic outbreak and has become a global health issue. In addition to primarily involving the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.
dc.languageeng
dc.publisherHellenic Journal of Cardiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectSevere acute respiratory syndrome coronavirus-2
dc.subjectMyocarditis
dc.subjectCholinergic anti-inflammatory pathway
dc.titleCOVID-19-related myocarditis and cholinergic anti-inflammatory pathways


Este ítem pertenece a la siguiente institución